<DOC>
	<DOCNO>NCT01005979</DOCNO>
	<brief_summary>The purpose study determine maximum tolerate dose ( MTD ) , safety toxicity cyclophosphamide , rituximab lenalidomide ( Revlimid ) combine treatment relapsed/refractory chronic lymphocytic leukemia ( CLL ) small lymphocytic lymphoma ( SLL ) .</brief_summary>
	<brief_title>A Phase I Trial Using Cyclophosphamide , Rituximab Revlimid ( CR2 ) Treatment Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia ( B-CLL ) Small Lymphocytic Lymphoma ( SLL )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<criteria>1 . Understand voluntarily sign informed consent form . 2 . Age ≥ 18 year time signing informed consent form . 3 . Able adhere study visit schedule protocol requirement . 4 . Relapsed/refractory Bcell CLL SLL 5 . All previous cancer therapy , include radiation , hormonal therapy surgery , must discontinue least 2 week prior treatment study . 6 . Patients must receive least one prior therapy must meet NCI Working Group ( NCI WG ) Criteria treatment BCLL describe Appendix D. 7 . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 study entry ( see Appendix C ) . 8 . Laboratory test result within range ( unless relate CLL involvement ) : Absolute neutrophil count ≥ 1000 /mm3 Platelet count ≥ 50,000/mm³ Serum creatinine ≤ 1.5 mg/dL . Serum creatinine &gt; 1.5 mg/dL require creatinine clearance ≥ 60 mL/min CockroftGault formula . Total bilirubin ≤ 1.5 mg/dL Aspartate aminotransferase ( AST ) ( SGOT ) alanine aminotransferase ( ALT ) ( SGPT ) ≤ 2 x upper limit normal ( ULN ) ≤ 5 x ULN hepatic metastasis present . 9 . Disease free second malignancy ≥ 5 year exception currently treat basal cell , squamous cell carcinoma skin , carcinoma `` insitu '' cervix breast . 10 . Females childbearing potential ( FCBP ) † must negative serum urine pregnancy test sensitivity least 50 milliInternational Units ( mIU ) /mL within 10 14 day prior within 24 hour start lenalidomide must either commit continued abstinence heterosexual intercourse begin TWO acceptable method birth control , one highly effective method one additional effective method AT THE SAME TIME , least 28 day start take lenalidomide . FCBP must also agree ongoing pregnancy test . Men must agree use latex condom sexual contact FCBP even successful vasectomy . All patient must counsel minimum every 28 day pregnancy precaution risk fetal exposure . See Appendix A : Risks Fetal Exposure , Pregnancy Testing Guidelines Acceptable Birth Control Methods , AND also Appendix B : Education Counseling Guidance Document . 11 . Able take aspirin ( 81 325 mg ) daily prophylactic anticoagulation ( patient intolerant acetylsalicylic acid [ ASA ] may use warfarin low molecular weight heparin ) . 1 . Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form . 2 . Pregnant breast feeding female . ( Lactating female must agree breast feed take lenalidomide ) . 3 . Any condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study confounds ability interpret data study . 4 . Evidence laboratory tumor lysis syndrome ( TLS ) CairoBishop criterion ( Appendix J ) ( subject may enrol upon correction electrolyte abnormality ) . 5 . Use experimental drug therapy within 28 day baseline . 6 . Known hypersensitivity thalidomide . 7 . The development erythema nodosum characterize desquamate rash take thalidomide similar drug . 8 . Any prior use lenalidomide . 9 . Concurrent use anticancer agent treatment . 10 . Known positive HIV infectious hepatitis , type A , B C .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Leukemia , Lymphocytic , Chronic , B-Cell</keyword>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>Lymphoma , Small Lymphocytic</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Leukemia</keyword>
</DOC>